Sodium-Glucose Cotransporter 2 Inhibitors

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) are indicated in the treatment of type II diabetes and work by decreasing the reabsorption of glucose in the renal tubules.  More glucose then escapes through the urinary system.  Yeast infections of the GU tract and urinary tract infections are more probable with these medications due to the increased levels of glucose in the urine.  

Class Drugs

• Canagliflozin

• Dapagliflozin

• Empagliflozin

Class Mechanism of Action

Inhibits sodium-glucose cotransporter 2 (SGLT2) in renal tubular lumen

• Decreases reabsorption of glucose in renal tubules, which results in urinary excretion of glucose

• Reabsorption of sodium also inhibited resulting in osmotic diuresis

Class Applications

Type II Diabetes Mellitus

Class Adverse Effects

Genital mycotic infections (vulvovaginitis, etc.)

Urinary tract infections

Urinary frequency

Hypotension

Drug Table

Drug Name	Application	Comments	Image
Canagliflozin			"Can" "Glitter" "Frozen"
Dapagliflozin			"Dapper" "Glitter" "Frozen"
Empagliflozin			"Empire State Building" "Glitter" "Frozen"